5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drugs in Development, 2021

5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drugs in Development, 2021

  • November 2021 •
  • 145 pages •
  • Report ID: 6189472 •
  • Format: PDF
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drugs in Development, 2021

Summary
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5’nucleotides.

5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 48 molecules. Out of which approximately 45 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 8, 5, 18 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Respiratory which include indications Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Unspecified Cancer, Pancreatic Cancer, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Oropharyngeal Cancer, Prostate Cancer, Colon Cancer, Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Non-Small Cell Lung Carcinoma, Oral Cavity (Mouth) Cancer, Renal Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anal Cancer, Angiosarcoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Cervical Cancer, Coronavirus Disease 2019 (COVID-19), Dedifferentiated Liposarcoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Fallopian Tube Cancer, Gastroesophageal (GE) Junction Carcinomas, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Papillomavirus (HPV) Associated Cancer, Idiopathic Pulmonary Fibrosis, Laryngeal Cancer, Lymphoma, Malignant Pleural Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Muscle Invasive Bladder Cancer (MIBC), Osteosarcoma, Peritoneal Cancer, Sarcomas and Uterine Cancer.

The latest report 5’ Nucleotidase - Drugs In Development, 2021, outlays comprehensive information on the 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.